نتائج البحث

A checklist for managed access programmes for reimbursement co-designed by Canadian patients and caregivers.

• Authors : Young A; Health Technology & Policy Unit, School of Public Health, University of Alberta, Edmonton, AB, Canada.; Menon D

Subjects: Caregivers* ; Checklist* ; Cooperative Behavior*

• Source: Health expectations : an international journal of public participation in health care and health policy [Health Expect] 2018 Dec; Vol. 21 (6), pp. 973-980. Date of Electronic Publisher: Wiley Country of Publication: England NLM ID: 9815926 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1369-7625

تفاصيل العنوان

Why Canada Still Needs an Orphan Drug Policy.

• Authors : Wong-Rieger, Durhane¹ (AUTHOR)

• Source: Maclean's. Apr2018, Vol. 131 Issue 3, p72-72. 1/3p. 1 Color Photograph.

تفاصيل العنوان

Moving beyond the Court of Public Opinion: A Citizens' Jury Exploring the Public's Values around Funding Decisions for Ultra-Orphan Drugs.

• Authors : Stafinski T; Health Technology & Policy Unit, School of Public Health, 4-343, Edmonton Clinic Health Academy, Edmonton, AB T6G 1C9, Canada.; Street J

Subjects: Public Opinion* ; Quality of Life*; Humans

• Source: International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Dec 30; Vol. 20 (1). Date of Electronic Publication: 2022 Dec 30.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601

تفاصيل العنوان

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.

• Authors : Nagase FNI; Health Technology & Policy Unit, School of Public Health, University of Alberta, Edmonton, AB, Canada. .; Stafinski T

Subjects: Rare Diseases/Rare Diseases/Rare Diseases/*drug therapy; Canada ; Cost-Benefit Analysis

• Source: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2019 Jun 07; Vol. 14 (1), pp. 127. Date of Electronic Publication: 2019 Jun 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172

تفاصيل العنوان

Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.

• Authors : Richter T; CADTH, 865 Carling Ave., Suite 600, Ottawa, ON, K1S 5S8, Canada.; Janoudi G

Subjects: Rare Diseases*; Canada ; Cost-Benefit Analysis

• Source: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2018 Feb 01; Vol. 13 (1), pp. 15. Date of Electronic Publication: 2018 Feb 01.Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172

تفاصيل العنوان

Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.

• Authors : McCormick JI; McKesson Specialty Health, 4705 Dobrin Street, Quebec, Saint-Laurent, H4R 2P7, Canada. .; Berescu LD

Subjects: Orphan Drug Production/Orphan Drug Production/Orphan Drug Production/*economics ; Technology Assessment, Biomedical/Technology Assessment, Biomedical/Technology Assessment, Biomedical/*methods; Advisory Committees

• Source: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2018 Jan 30; Vol. 13 (1), pp. 27. Date of Electronic Publication: 2018 Jan 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172

تفاصيل العنوان

Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare.

• Authors : Shah J; Department of Social Policy, London School of Economics and Political Science, and is now at the Canadian Institutes of Health Research, 410 Laurier Avenue West (11th Floor), Ottawa, Ontario K1A 0W9, Canada.

Subjects: Drug Approval/Drug Approval/Drug Approval/*economics ; Drug Approval/Drug Approval/Drug Approval/*legislation & jurisprudence ; Health Care Sector/Health Care Sector/Health Care Sector/*legislation & jurisprudence

• Source: Nature biotechnology [Nat Biotechnol] 2003 Jul; Vol. 21 (7), pp. 747-53.Publisher: Nature America Publishing Country of Publication: United States NLM ID: 9604648 Publication Model: Print Cited Medium: Print ISSN:

تفاصيل العنوان

State of rare disease management in Southeast Asia.

• Authors : Shafie, Asrul Akmal¹ ; Chaiyakunapruk, Nathorn^2,3,4,5; Supian, Azuwana¹

• Source: Orphanet Journal of Rare Diseases. 8/2/2016, Vol. 11, p1-11. 11p.

تفاصيل العنوان

Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.

• Authors : Divino, Victoria¹ ; DeKoven, Mitch¹; Kleinrock, Michael²

• Source: Orphanet Journal of Rare Diseases. 5/21/2016, Vol. 11, p1-8. 8p.

تفاصيل العنوان

Permissive regulation: How North America's regulation of buprenorphine supported manufacturer profits over equitable access.

• Authors : McGee, Meghan

• Source: Annals of Family Medicine. 2023 Supplement, Vol. 21, p1-2. 2p.

تفاصيل العنوان